Amgen and Allergan have launched their biosimilar competitors to two of Roche's top-selling cancer drugs in the U.S., according to PharmaPhorum.
Four things to know:
1. The companies said that the initial list price for the two drugs will be 15 percent lower than the price of their reference product.
2. Amgen launched Mvasi, a biosimilar to Avastin. It will be available at a wholesale cost of $677.4 per 100 milligrams and $2,709.60 for a single-dose vial.
3. Allergan has launched Kanjiti, a biosimilar to Herceptin. It will be available at $3,697.26 per 420-milligram vial.
4. Herceptin and Avastin together brought in sales of $5.8 billion in 2018 for Roche.
Read the full report here.
More articles on pharmacy:
Oklahoma opioid trial wraps: 10 takeaways
Drugmaker tried to shred records before FDA inspection, agency claims
Publix Pharmacy to deliver prescriptions to patients before hospital discharge